Nykode Therapeutics AS reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 5 million compared to USD 3.11 million a year ago. Revenue was USD 5.1 million compared to USD 3.42 million a year ago. Net loss was USD 9.21 million compared to USD 8.75 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.03 compared to USD 0.03 a year ago.
For the six months, sales was USD 8.13 million compared to USD 3.83 million a year ago. Revenue was USD 8.41 million compared to USD 4.45 million a year ago. Net loss was USD 19.57 million compared to USD 15.65 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.05 a year ago. Diluted loss per share from continuing operations was USD 0.07 compared to USD 0.05 a year ago.